Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19

Covid19 Clinical Trial

Official title: Preemptive Use of Convalescent Plasma for High-risk Patients With SARS-CoV-2 Infection: Phase III-IV Non-controlled Non-randomised Swiss Multicentric Trial

Status Recruiting

Clinical Trial Summary

Convalescent plasma therapy has been recognized as safe and plasma transfusion is routinely used in clinical practice. A recent study showed that early administration of convalescent plasma can decrease the risk of complications in specific high-risk population.

The aim of the present study is to offer convalescent plasma therapy to immunocompromised patients and older adults in the early phase of a SARS-Cov-2 infection in order to accelerate viral clearance and prevent complication

Clinical Trial Description

This is an open-label non-controlled, non-randomised interventional study. Study population consist in immunocompromised patients and older adults with or without co-morbidities.

Included patients will receive at least one unit of convalescent plasma with NTAB titer ≥1:160 or equivalent at maximum 3-7 days after diagnosis by RT-PCR or symptom onset or if having mild-moderate disease (WHO scale <4).

Patients will be followed-up up to 28 days to assess progression to WHO scale 4 disease, and 28-days mortality and viral load kinetics. ;

Related Conditions & MeSH terms

• Covid19
• Immuno-Deficiency
• Immunologic Deficiency Syndromes
• Old Age; Debility

• NCT number: NCT04836260
• Study type: Interventional
• Source: University Hospital, Geneva
• Contact: Diem-Lan Vu Cantero, MD, PhD
• Phone: +41795535512
• Email: diem-lan.vu@hcuge.ch
• Status: Recruiting
• Phase: Phase 3
• Start date: April 8, 2021
• Completion date: December 31, 2021